John Pullman

Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial

George R. Thompson, Àlex Soriano, Oliver A. Cornely et al. · The Lancet · 2022 · 168 citations · Full text

Life Sciences, Microbiology, Pharmacology +16

Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials

George R. Thompson, Àlex Soriano, Patrick M. Honoré et al. · The Lancet Infectious Diseases · 2023 · 73 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19

Teresa H. Evering, Mark J Giganti, Carlee Moser et al. · Annals of Internal Medicine · 2023 · 31 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials

Patrick M. Honoré, Massimo Girardis, Marin H. Kollef et al. · Critical Care · 2024 · 16 citations · Full text

Pharmacy, Pharmacotherapy, Antimicrobial Pharmacotherapy +16